Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They presently have a $155.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 5.76% from the company’s previous close.
Other research analysts have also issued reports about the company. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Truist Financial raised their price target on Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.26.
Get Our Latest Research Report on Gilead Sciences
Gilead Sciences Stock Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the business posted $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts expect that Gilead Sciences will post -0.48 earnings per share for the current year.
Insider Transactions at Gilead Sciences
In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the transaction, the chief financial officer owned 164,096 shares of the company’s stock, valued at approximately $23,841,507.84. This trade represents a 1.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock valued at $14,940,540 in the last 90 days. Insiders own 0.30% of the company’s stock.
Institutional Trading of Gilead Sciences
Institutional investors have recently bought and sold shares of the business. Davidson Trust Co. increased its holdings in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 74 shares during the period. Financial Connections Group Inc. increased its stake in Gilead Sciences by 30.2% in the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares during the last quarter. Wilkerson Advisory Group LLC increased its stake in Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares during the last quarter. Balboa Wealth Partners increased its stake in Gilead Sciences by 2.7% in the first quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 79 shares during the last quarter. Finally, HBW Advisory Services LLC increased its stake in Gilead Sciences by 2.4% in the first quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock valued at $473,000 after acquiring an additional 79 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: JPMorgan raised its price target from $160 to $170 and reaffirmed an “overweight” rating, implying meaningful upside and reflecting confidence in Gilead’s earnings and growth outlook.
- Positive Sentiment: Truist increased its target from $150 to $158 and maintained a “buy” rating, while Cantor Fitzgerald reaffirmed “overweight” with a $155 target. Together, these calls support investor confidence in the stock’s potential.
- Positive Sentiment: Gilead signed a five-year DevOps agreement with Cognizant. The partnership is intended to improve technology infrastructure and business processes by combining Cognizant’s technical capabilities with life-sciences expertise, potentially supporting operational efficiency. Gilead Sciences signs five-year DevOps agreement with Cognizant
- Positive Sentiment: Nurix Therapeutics extended the research term of its Gilead collaboration by two years for an oncology program. The extension indicates continued progress in Gilead’s protein-degradation research pipeline and preserves potential future development opportunities.
- Neutral Sentiment: Morgan Stanley lowered its target modestly from $165 to $163 but retained an “overweight” rating, signaling continued confidence despite slightly reduced expectations.
- Neutral Sentiment: Gilead shares were reported higher in after-hours European trading, but the move does not identify a specific fundamental catalyst and may have limited relevance for U.S. investors.
- Negative Sentiment: Royal Bank of Canada raised its target from $123 to $126 but kept a “sector perform” rating. The new target remains below Gilead’s recent trading level, highlighting valuation concerns and potential downside. Gilead Sciences analyst coverage from Royal Bank of Canada
- Negative Sentiment: A recent analysis argued that Gilead’s growth comes at a high price, with discounted-cash-flow assumptions pointing to valuation risk. This could weigh on sentiment despite the more optimistic analyst targets. Gilead: Buying Growth Isn’t Free, And The Discounted Cash Flow Model Knows It
About Gilead Sciences
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
